Evidence map›Paper›PMID 28126302›Full record

ArticleInternational journal of radiation oncology, biology, physics2017

Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography.

William P Parker, Jaden D Evans, Bradley J Stish, Sean S Park, Kenneth Olivier, Richard Choo, Mark A Nathan, Brian T Welch, R Jeffrey Karnes, Lance A Mynderse and 4 more

Abstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Prospective Immunophenotyping of CD8International journal of radiation oncology, biology, physics · 2019
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Analysis of FDA-approved imaging agents.Drug discovery today · 2017
    Review
  10. Advances in radiation oncology
    Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

William P ParkerDepartment of Urology, Mayo Clinic, Rochester, Minnesota.
Jaden D EvansDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Bradley J StishDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Sean S ParkDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Kenneth OlivierDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Richard ChooDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Mark A NathanDepartment of Radiology, Mayo Clinic, Rochester, Minnesota.
Brian T WelchDepartment of Radiology, Mayo Clinic, Rochester, Minnesota.
R Jeffrey KarnesDepartment of Urology, Mayo Clinic, Rochester, Minnesota.
Lance A MynderseDepartment of Urology, Mayo Clinic, Rochester, Minnesota.
Thomas M PisanskyDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Eugene D KwonDepartment of Urology, Mayo Clinic, Rochester, Minnesota.
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, Minnesota.
Brian J DavisDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. Electronic address: davis.brian@mayo.edu.
Mayo Clinic · US

Funding

A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABRR01CA200551 · NCI · MAYO CLINIC ROCHESTER · PI DONG, HAIDONG, PARK, SEAN S · 2016 to 2018
$739k
NCI NIH HHS R01 CA200551
6 · The paper itself

Abstract

purposeTo evaluate C-11 choline positron emission tomography/computed tomography (CholPET) in staging and determining patterns of recurrence in prostate cancer patients with rising prostate-specific antigen levels after prostatectomy radiation therapy (RT). METHODS AND MATERIALS: The study includes patients with biochemical failure after postprostatectomy RT who underwent CholPET between 2008 and 2015. Patient and disease characteristics were examined in relation to sites of recurrence. All RT dosimetry records were reviewed, and recurrences were mapped on a representative computed tomography dataset with their relationship relative to the irradiated fossa field as out of field (OOF), edge of field (EOF; recurrence within <45-Gy isodose lines), or in field (IF; recurrence within ≥45-Gy isodose lines).

resultsForty-one patients were identified with 121 sites of recurrence (median 2 sites; interquartile range [IQR], 1-4). The median prostate-specific antigen level at CholPET was 3.1 (IQR, 1.9-5.6) ng/mL. Median interval from RT to biochemical failure was 24 (IQR, 10-46) months, with recurrence identified on CholPET at a median of 15 (IQR, 7-28) months from biochemical failure. Histologic confirmation of recurrence was obtained in 20 patients (49%), with the remainder confirmed by treatment response. Five patients (12%) had IF recurrences, 10 patients (24%) had EOF recurrences (median dose 10 Gy; IQR, 5-30 Gy), and 36 patients (88%) had OOF recurrences. Ten patients had combination failures: 6 (15%) EOF/OOF and 4 (10%) IF/OOF. Fifty-seven recurrences (47%) were pelvic nodal sites inferior to the L5-S1 interspace, of which 52 (43%) were within a pelvic RT field. Eighty-one recurrences (67%) were nodal and inferior to the aortic bifurcation.

conclusionsUsing CholPET, we found that the majority of patients evaluated for biochemical failure recurred outside of the postprostatectomy RT field. Furthermore, most recurrence sites were nodal and inferior to the aortic bifurcation. These results provide data that may be useful for examining strategies that include elective lymph node irradiation in postprostatectomy patients.

Indexed as

Positron Emission Tomography Computed TomographyProstatectomyAgedBone NeoplasmsCarbon RadioisotopesCholineHumansLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalPostoperative CareProstate-Specific AntigenProstatic NeoplasmsStatistics, NonparametricCarbon RadioisotopesCholineProstate-Specific Antigen

Identifiers

PMID28126302
PMCPMC5308881
OpenAlexW2555296848

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.